Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Stat1

Journal of Immunology

Volumn 163, Issue 8, 1999, Pages 4109-4113

  Fallarino, Francesca ^a   Gajewski, Thomas F ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; SERINE PROTEINASE; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR REJECTION;

EID: 0032824424     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
2. Gajewski, T. F., C. Uyttenhove, F. Fallarino, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
3. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095.
4. Schmits, R., T. M. Kundig, D. M. Baker, G. Shumaker, J. J. L. Simard, G. Duncan, A. Wakeham, A. Shahinian, A. Van der Heiden, M. F. Bachmann, P. S. Ohashi, T. W. Mak, and D. D. Hickstein. 1996. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J. Exp. Med. 183:1415.
5. Van der Broek, M. E., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781.
6. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556.
7. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski. 1999. Improved efficacy of dendritic cell vaccines, and successful immunization with tumor antigen peptide-pulsed PBMC, by co-administration of rmIL-12. Int. J. Cancer. 80:324.
8. Gabrilovich, D. I., H. T. Cunningham, and D. P. Carbone. 1997. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J. Immunother. 19:414.
9. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
10. Gajewski, T. F., F. Fallarino, N. Vogelzang, M. C. Posner, A. Ashikari, and M. L. Sherman. 1999. Effective melanoma antigen immunization without dendritic cells (DC): a phase I study of immunization with Mage3 or Melan-A peptide-pulsed autologous PBMC plus rhIL-12. Proc. ASCO 18:539a.
11. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver-Moore, R. N. DuBois, R. Clark, M. Aguet, and R. D. Schreiber. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity of the JAK-STAT signaling pathway. Cell 84:431.
12. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443.
13. Cousens, L. P., R. Peterson, S. Hsu, A. Dorner, J. D. Alyman, R. Ahmed, and C. A. Biron. 1999. Two roads diverged: interferon α/β -and interleukin-12-mediated pathways in promoting T cell interferon γresponses during viral infection. J. Exp. Med. 189:1315.
14. Van Pel, A., E. De Plaen, and T. Boon. 1985. Selection of a highly transfectable variant from mouse mastocytoma P815. Somat. Cell Mol. Genet. 11:467.
15. - transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp. Med. 172:35.
16. Fallarino, F., A. Ashikari, T. Boon, and T. F. Gajewski. 1997. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells. Int. Immunol. 9:1259.
17. Gajewski, T. F., J.-C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154:5637.
18. Hayes, M. P., G. A. Berrebi, and P. A. Henkart. 1989. Induction of target cell DNA release by the cytotoxic T lymphocyte granule protease granzyme A. J. Exp. Med. 170:933.
19. Suhrbier, A., A. Fernan, S. R. Burrows, A. Saul, and D. J. Moss. 1991. BLT esterase activity as an alternative to chromium release in cytotoxic T cell assays. J. Immunol. Methods. 145:43.
20. Rao, J. B., R. S. Chamberlain, V. Bronte, M. W. Carroll, K. R. Irvine, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1996. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156:3357.
21. Tuting, T., A. Gambotto, A. DeLeo, M. T. Lotze, P. D. Robbins, and W. J. Storkus. 1999. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. 6:73.
22. Tahara, H., H. J. Zeh, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182.
23. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of IFN-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17:71.
24. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
25. Villacres, M. C., and C. C. Bergmann. 1999. Enhanced cytotoxic T cell activity in IL-4-deficient mice. J. Immunol. 162:2663.
26. + T cells. J. Exp. Med. 178:1655.
27. Hardy, K. J., and T. Sawada. 1989. Human γ-interferon strongly up-regulates its own gene expression in peripheral blood lymphocytes. J. Exp. Med. 170:1021.
28. H2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-γ. J. Immunol. 143:15.
29. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Anna. Rev. Immunol. 17:189.
30. + T cells and monocytes. Blood 87:4731.
31. McRae, B. L., R. T. Semnani, M. P. Hayes, and G A. van Seventer. 1998. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160:4298.
32. Wong, L. H., K. G. Krauer, I. Hatzinsiriou, M. J. Estcourt, P. Hersey, N. D. Tam, S. Edmondson, R. J. Devenish, and S. J. Ralph. 1997. Interferon-resistant human melanoma cells are deficient in ISGF3 components, Stat1, Stat2, and p48ISGF3γ. J. Biol. Chem. 272:28779.
33. Frank, D. A., S. Mahajan, and J. Ritz. 1999. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 5:444.